Uppsala, Sweden
Founded: 2000

Why It's Fierce: The company's products streamline laboratory testing, allowing researchers to generate more scientific information from smaller biological samples. Two-year-old Gyros has attracted an impressive list of former Pharmacia executives and backing from some of Europe's leading venture capitalists. The venture capital bust is bad in America. It's even worse in Europe. We think Gyros is a survivor.

What to look for in 2003: Gyros' strong finances and industry contacts will help the company gain traction this year as its competitors wither on the vine.



Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.